EEG
MNTA

E.E. Geduld’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

E.E. Geduld’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-15,000
Closed -$342K – 291
2015
Q2 		$342K Buy
+15,000
New +$299K 0.21% 103

Other funds holding MNTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

E.E. Geduld's MNTA Position: Q3 2015 in Review

E.E. Geduld sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2015, closing a stake of 15,000 shares — an estimated $342K sold.

E.E. Geduld first reported a position in MNTA in Q2 2015 and held it in 1 quarter. The position peaked at $342K in Q2 2015. 156 funds tracked by Wall St. Rank hold MNTA as of Q3 2015.

  • E.E. Geduld reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2015 after selling out during the quarter.
  • E.E. Geduld sold 15,000 Momenta Pharmaceuticals, Inc. shares in Q3 2015, an estimated $342K.
  • E.E. Geduld first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2015 and held it in 1 quarter.
  • E.E. Geduld's Momenta Pharmaceuticals, Inc. position peaked at $342K in Q2 2015.
  • 156 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2015.

Based on E.E. Geduld's 13F filing for Q3 2015, filed 6 Nov 2015.